Comparative Pharmacology
Head-to-head clinical analysis: CYCLESSA versus ELINEST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLESSA versus ELINEST.
CYCLESSA vs ELINEST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of estrogen (ethinyl estradiol) and progestin (desogestrel) inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus to impede sperm penetration, and alters endometrial receptivity.
Ethinyl estradiol is an estrogen; drospirenone is a progestin with anti-mineralocorticoid and anti-androgenic activity. The combination suppresses gonadotropins, inhibiting ovulation.
One tablet (0.15 mg desogestrel/0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
0.5 mg orally once daily.
None Documented
None Documented
Desogestrel: 38±13 hours (terminal); ethinyl estradiol: 14±3 hours (terminal). Steady-state reached after 7-10 days.
Terminal elimination half-life of estradiol (E2) is ~13-16 h, but due to the prodrug nature and accumulation of estrogen metabolites, the effective half-life during continuous use is ~36 h, supporting once-daily dosing.
Urine (50-60% as metabolites, <10% unchanged); feces (30-40% as metabolites); enterohepatic circulation.
~68% renal (50% unchanged, ~18% as inactive metabolites), ~30% biliary/fecal, with enterohepatic recycling of drug and estrogen conjugates.
Category C
Category C
Oral Contraceptive
Oral Contraceptive